ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (ACVDL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01481194
Recruitment Status : Active, not recruiting
First Posted : November 29, 2011
Last Update Posted : February 9, 2018
The University of Hong Kong
Information provided by (Responsible Party):
Vejle Hospital

November 21, 2011
November 29, 2011
February 9, 2018
November 2011
May 2014   (Final data collection date for primary outcome measure)
Response rate [ Time Frame: 4 weeks after completion of 8 treatment cycles ]
Same as current
Complete list of historical versions of study NCT01481194 on Archive Site
  • Complete response rate [ Time Frame: 4 weeks after completion of 8 treatment cycles ]
  • Very good partial response rate [ Time Frame: 4 weeks after completion of 8 treatment cycles ]
  • Time to progression [ Time Frame: 4 years ]
  • Progression free survival [ Time Frame: 4 years ]
Same as current
Not Provided
Not Provided
ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination With Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of the combination treatment of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide in newly diagnosed multiple myeloma patients.
Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Doxorubicin
    50 mg/m2 IV on day 1 of a 21-day cycle
  • Drug: Bortezomib
    1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
  • Drug: Lenalidomide
    15 mg orally on days 1-14 of a 21-day cycle
  • Drug: Dexamethasone
    20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
  • Drug: Cyclophosphamide
    750 mg/m2 IV on day 1 of a 21-day cycle
Experimental: ACVDL
ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
  • Drug: Doxorubicin
  • Drug: Bortezomib
  • Drug: Lenalidomide
  • Drug: Dexamethasone
  • Drug: Cyclophosphamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
December 2019
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female subjects ≥ 18 years at the time of signing informed consent.
  2. Subject is diagnosed with symptomatic multiple myeloma based on the International Myeloma Working Group Diagnostic Criteria (Kyle 2009):

    • Monoclonal plasma cells in the bone marrow ≥ 10% and/or presence of a biopsy-proven plasmacytoma.
    • Monoclonal protein present in the serum and/or urine. If no monoclonal protein is detected (non-secretory disease), then ≥ 30% monoclonal bone marrow plasma cells and/or a biopsy-proven plasmacytoma is required.
    • Myeloma-related organ dysfunction
  3. The myeloma disease burden must be measurable with at least one of the following criteria (Durie et al. 2006):

    • Serum M-protein ≥ 10 g/l
    • Urine M-protein ≥ 200 mg/24 h
    • Involved FLC ≥ 100 mg/l provided serum FLC ratio is abnormal
    • Bone marrow plasma cells > 30%
  4. Subject has a Karnofsky performance status of ≥ 60.
  5. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  6. Subject is willing and able to comply with the protocol as judged by the investigator.

Exclusion Criteria:

  1. Any prior systemic therapy for multiple myeloma.
  2. Other therapies such as biologic therapy and chemotherapy less than 3 months prior to screening.
  3. Any prior treatment with doxorubicin or other anthracycline.
  4. Concurrent or recent (less than 2 weeks prior to Screening) radiotherapy or surgery.
  5. Prior glucocorticoid treatment of multiple myeloma exceeding dexamethasone 20mg/day for a maximum of 7 days. Topical glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted.
  6. More than or equal to grade 2 peripheral neuropathy according to the NCI-CTC criteria on clinical examination within 14 days before enrolment (Day 1 of Cycle 1).
  7. Evidence of mucosal or internal bleeding and/or platelet counts < 50 x 10^9/l. Platelet transfusions may not be used to meet PLT eligibility criteria.
  8. Absolute neutrophil count (ANC) < 1 x 10^9/l. Growth factors may not be used to meet ANC eligibility criteria.
  9. Hemoglobin < 5.0 mmol/l. The subject may be included after correction of the hemoglobin level by transfusion or treatment with erythropoietin.
  10. Alanine aminotransferase (ALAT) > 2 x ULN.
  11. Myocardial infarction within 6 months prior to enrolment or New York Heart Association (NYHA) Class IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
  12. Clinically relevant active infection or serious co-morbid medical conditions, such as chronic obstructive or chronic restrictive pulmonary disease, and cirrhosis.
  13. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at unacceptable risk if he/she were to participate in the study.
  14. Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, or in situ prostate cancer for which the subject has been disease-free for at least 3 years.
  15. Female subject is pregnant or breast-feeding. The first serum pregnancy test to be done within 10-14 days prior to the study treatment start and repeated serum pregnancy test to be done within 24 hours prior to the start of study treatment.
  16. Female subjects who are of childbearing potential (biologically capable of becoming pregnant) or men with partners of childbearing potential, who are unwilling or unable to use effective means of contraception. The means of contraception must be TWO acceptable methods of birth control, one highly effective method (hormonal contraceptives pills, injections or implants, tubal ligation, partner's vasectomy) and one additional effective method (condom, diaphragm, cervical cap) AT THE SAME TIME, at least 28 days before she or he starts ACVDL and for at least 28 days after the last dose of ACVDL.
  17. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  18. Uncontrolled diabetes mellitus at the discretion of the investigator.
  19. Hypersensitivity and/or contraindication to any one of the Investigational Medicinal Products (IMP), acyclovir or similar anti-viral drug.
  20. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes).
  21. Known HIV infection.
  22. Known active hepatitis B or C viral infection.
  23. Known intolerance to steroid therapy.
  24. Current or recent (within 30 days prior to Screening) treatment with another investigational drug.
  25. Unable to comply with the administration of the study treatment.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Vejle Hospital
Vejle Hospital
The University of Hong Kong
Study Chair: Torben Plesner, DMSc Vejle Hospital
Vejle Hospital
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP